|
|
|
Insider
Information: |
Gosebruch Henry O |
Relationship: |
|
City: |
North Chicago |
State: |
IL |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
4 |
|
Direct
Shares |
553,968 |
|
Indirect Shares
|
324,586 |
|
|
Direct
Value |
$14,278,926 |
|
|
Indirect Value
|
$12,840,002 |
|
|
Total
Shares |
878,554 |
|
|
Total
Value |
$27,118,928 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
2
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
2
|
0
|
|
|
|
Gain/Loss Ratio : |
-2.0
|
0.0
|
Percentage
Gain/Loss : |
-44.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Abbvie Inc. |
ABBV |
EVP, Chief Strategy Of... |
2022-05-16 |
41,623 |
2022-05-16 |
57,138 |
Premium* |
|
Aptinyx Inc. |
APTX |
Director |
2019-10-04 |
0 |
2020-01-10 |
125,000 |
Premium* |
|
Acelyrin, Inc. |
SLRN |
Director |
2023-05-09 |
50,000 |
2023-05-09 |
0 |
Premium* |
|
Neumora Therapeutics, Inc. |
NMRA |
|
2024-02-14 |
462,345 |
2024-02-14 |
142,448 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 1
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
APTX |
Aptinyx Inc. |
Director |
|
2019-10-04 |
4 |
GD |
$0.00 |
$0 |
D/D |
100,000 |
0 |
0 |
- |
|
APTX |
Aptinyx Inc. |
Director |
|
2019-10-04 |
4 |
GA |
$0.00 |
$0 |
I/I |
100,000 |
100,000 |
0 |
- |
|
APTX |
Aptinyx Inc. |
Director |
|
2019-05-08 |
4 |
B |
$3.86 |
$372,799 |
D/D |
96,580 |
100,000 |
2.39 |
- |
|
ABBV |
Abbvie Inc. |
Chief Strategy Officer |
|
2015-12-09 |
4 |
A |
$0.00 |
$0 |
D/D |
91,050 |
91,050 |
0 |
- |
|
ABBV |
Abbvie Inc. |
EVP, Chief Strategy Officer |
|
2022-05-16 |
4 |
S |
$155.00 |
$13,013,800 |
D/D |
(83,960) |
16,623 |
0 |
- |
|
ABBV |
Abbvie Inc. |
EVP, Chief Strategy Officer |
|
2022-05-16 |
4/A |
S |
$155.00 |
$13,013,800 |
D/D |
(83,960) |
41,623 |
0 |
- |
|
ABBV |
Abbvie Inc. |
EVP, Chief Strategy Officer |
|
2022-05-16 |
4 |
OE |
$54.86 |
$4,606,046 |
D/D |
83,960 |
100,583 |
0 |
- |
|
ABBV |
Abbvie Inc. |
EVP, Chief Strategy Officer |
|
2022-05-16 |
4/A |
OE |
$54.86 |
$4,606,046 |
D/D |
83,960 |
125,583 |
0 |
- |
|
NMRA |
Neumora Therapeutics, Inc... |
President & CEO |
|
2024-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
80,000 |
462,345 |
0 |
- |
|
ABBV |
Abbvie Inc. |
EVP, Chief Strategy Officer |
|
2022-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
68,068 |
86,779 |
0 |
- |
|
ABBV |
Abbvie Inc. |
EVP, Chief Strategy Officer |
|
2020-02-20 |
4 |
A |
$0.00 |
$0 |
D/D |
58,781 |
104,544 |
0 |
- |
|
ABBV |
Abbvie Inc. |
EVP, Chief Strategy Officer |
|
2019-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
51,815 |
68,719 |
0 |
- |
|
ABBV |
Abbvie Inc. |
EVP, Chief Strategy Officer |
|
2021-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
51,538 |
71,544 |
0 |
- |
|
SLRN |
Acelyrin, Inc. |
Director |
|
2023-05-09 |
4 |
B |
$18.00 |
$900,000 |
D/D |
50,000 |
50,000 |
2.39 |
% |
|
ABBV |
Abbvie Inc. |
EVP, Chief Strategy Officer |
|
2018-11-29 |
4 |
S |
$90.10 |
$3,824,940 |
D/D |
(42,450) |
30,350 |
0 |
- |
|
ABBV |
Abbvie Inc. |
EVP, Chief Strategy Officer |
|
2020-11-20 |
4 |
S |
$98.83 |
$3,975,046 |
D/D |
(40,000) |
20,006 |
0 |
- |
|
ABBV |
Abbvie Inc. |
EVP, Chief Strategy Officer |
|
2018-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
39,316 |
90,218 |
0 |
- |
|
ABBV |
Abbvie Inc. |
EVP, Chief Strategy Officer |
|
2022-02-25 |
4 |
D |
$149.54 |
$4,509,528 |
D/D |
(30,156) |
56,623 |
0 |
- |
|
ABBV |
Abbvie Inc. |
EVP, Chief Strategy Officer |
|
2019-07-29 |
4 |
B |
$67.28 |
$2,018,385 |
D/D |
30,000 |
75,763 |
2.74 |
- |
|
ABBV |
Abbvie Inc. |
EVP, Chief Strategy Officer |
|
2019-08-14 |
4 |
GD |
$0.00 |
$0 |
D/D |
30,000 |
45,763 |
0 |
- |
|
ABBV |
Abbvie Inc. |
EVP, Chief Strategy Officer |
|
2019-08-14 |
4 |
GA |
$0.00 |
$0 |
I/I |
30,000 |
30,000 |
0 |
- |
|
ABBV |
Abbvie Inc. |
EVP, Chief Strategy Officer |
|
2021-09-07 |
4 |
GD |
$0.00 |
$0 |
D/D |
30,000 |
18,711 |
0 |
- |
|
ABBV |
Abbvie Inc. |
EVP, Chief Strategy Officer |
|
2021-09-07 |
4 |
GA |
$0.00 |
$0 |
I/I |
30,000 |
78,500 |
0 |
- |
|
ABBV |
Abbvie Inc. |
EVP, Chief Strategy Officer |
|
2020-02-28 |
4 |
D |
$85.42 |
$2,224,166 |
D/D |
(26,038) |
78,506 |
0 |
- |
|
APTX |
Aptinyx Inc. |
Director |
|
2020-01-10 |
4 |
B |
$3.00 |
$75,000 |
I/I |
25,000 |
125,000 |
2.1 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|